Glycosylation of blood cells during the onset and progression of atherosclerosis and myocardial infarction.

Autor: Ferro F; CÚRAM, SFI Research Centre for Medical Devices, University of Galway, Galway, Ireland; Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy., Spelat R; CÚRAM, SFI Research Centre for Medical Devices, University of Galway, Galway, Ireland; Neurobiology Sector, International School for Advanced Studies (SISSA), Trieste, Italy., Pandit A; CÚRAM, SFI Research Centre for Medical Devices, University of Galway, Galway, Ireland., Martin-Ventura JL; Vascular Research Laboratory, IIS-Fundación Jiménez-Díaz, Madrid, Spain; CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Electronic address: jlmartin@fjd.es., Rabinovich GA; Laboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina; Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina. Electronic address: gabyrabi@gmail.com., Contessotto P; CÚRAM, SFI Research Centre for Medical Devices, University of Galway, Galway, Ireland; Department of Molecular Medicine, University of Padua, Padua, Italy. Electronic address: paolocontessotto@gmail.com.
Jazyk: angličtina
Zdroj: Trends in molecular medicine [Trends Mol Med] 2024 Feb; Vol. 30 (2), pp. 178-196. Date of Electronic Publication: 2023 Dec 22.
DOI: 10.1016/j.molmed.2023.11.013
Abstrakt: Protein glycosylation controls cell-cell and cell-extracellular matrix (ECM) communication in immune, vascular, and inflammatory processes, underlining the critical role of this process in the identification of disease biomarkers and the design of novel therapies. Emerging evidence highlights the critical role of blood cell glycosylation in the pathophysiology of atherosclerosis (ATH) and myocardial infarction (MI). Here, we review the role of glycosylation in the interplay between blood cells, particularly erythrocytes, and endothelial cells (ECs), highlighting the involvement of this critical post/cotranslational modification in settings of cardiovascular disease (CVD). Importantly, we focus on emerging preclinical studies and clinical trials based on glycan-targeted drugs to validate their therapeutic potential. These findings may help establish new trends in preventive medicine and delineate novel targeted therapies in CVD.
Competing Interests: Declaration of interests The authors declare no competing interests.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: